180 related articles for article (PubMed ID: 38116487)
21. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma.
Wieczorek A; Zaniewska-Tekieli A; Ehlert K; Pawinska-Wasikowska K; Balwierz W; Lode H
Front Oncol; 2023; 13():1082771. PubMed ID: 36816982
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
[TBL] [Abstract][Full Text] [Related]
23. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
[TBL] [Abstract][Full Text] [Related]
24. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
25. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava.
Achbergerová M; Hederová S; Hrašková A; Kolenová A
Medicine (Baltimore); 2022 Jan; 101(4):e28716. PubMed ID: 35089239
[TBL] [Abstract][Full Text] [Related]
26. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G
J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model.
Zoine JT; Knight KA; Fleischer LC; Sutton KS; Goldsmith KC; Doering CB; Spencer HT
Oncoimmunology; 2019; 8(8):1593804. PubMed ID: 31413905
[TBL] [Abstract][Full Text] [Related]
28. Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series.
Gartrell J; Shulkin BL; Helmig S; Caldwell KJ; Furman W; Federico SM
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e692-e696. PubMed ID: 33181583
[TBL] [Abstract][Full Text] [Related]
29. Dinutuximab: first global approval.
Dhillon S
Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
[TBL] [Abstract][Full Text] [Related]
30. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.
Olgun N; Cecen E; Ince D; Kizmazoglu D; Baysal B; Onal A; Ozdogan O; Guleryuz H; Cetingoz R; Demiral A; Olguner M; Celik A; Kamer S; Ozer E; Altun Z; Aktas S
Front Oncol; 2022; 12():1041443. PubMed ID: 36620564
[TBL] [Abstract][Full Text] [Related]
31. Rhombencephalitis and longitudinal extensive myelitis associated with dinutuximab use in high-risk neuroblastoma.
Atak F; Aydın GB; Öncel İ; Öz S; Oğuz KK
Turk J Pediatr; 2023; 65(3):523-530. PubMed ID: 37395971
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
Troschke-Meurer S; Zumpe M; Meißner L; Siebert N; Grabarczyk P; Forkel H; Maletzki C; Bekeschus S; Lode HN
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765861
[TBL] [Abstract][Full Text] [Related]
33. Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data.
Wieczorek A; Żebrowska U; Ussowicz M; Sokół A; Stypińska M; Dembowska-Bagińska B; Pawińska-Wąsikowska K; Balwierz W
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629294
[TBL] [Abstract][Full Text] [Related]
34. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
[No Abstract] [Full Text] [Related]
35. Dinutuximab: A Review in High-Risk Neuroblastoma.
Hoy SM
Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
[TBL] [Abstract][Full Text] [Related]
36. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
37. Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma.
Launspach M; Seif M; Thole TM; Jesse P; Schulz J; Schulte JH; Bischoff S; Eggert A; Deubzer HE
Children (Basel); 2021 Jan; 8(2):. PubMed ID: 33572828
[TBL] [Abstract][Full Text] [Related]
38. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
Ding YY; Panzer J; Maris JM; Castañeda A; Gomez-Chiari M; Mora J
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748630
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy with anti-G
Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
[TBL] [Abstract][Full Text] [Related]
40. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.
Ornell KJ; Taylor JS; Zeki J; Ikegaki N; Shimada H; Coburn JM; Chiu B
Cancer Med; 2020 Apr; 9(8):2891-2903. PubMed ID: 32096344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]